Werewolf Therapeutics (HOWL) Competitors $1.41 +0.01 (+0.71%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.40 0.00 (-0.35%) As of 07/18/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOWL vs. OGI, NLTX, PROK, ALMS, ELDN, CYBN, TIL, PBYI, VYGR, and TLSAShould you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include Organigram Global (OGI), Neoleukin Therapeutics (NLTX), ProKidney (PROK), Alumis (ALMS), Eledon Pharmaceuticals (ELDN), Cybin (CYBN), Instil Bio (TIL), Puma Biotechnology (PBYI), Voyager Therapeutics (VYGR), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry. Werewolf Therapeutics vs. Its Competitors Organigram Global Neoleukin Therapeutics ProKidney Alumis Eledon Pharmaceuticals Cybin Instil Bio Puma Biotechnology Voyager Therapeutics Tiziana Life Sciences Organigram Global (NASDAQ:OGI) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability. Do analysts rate OGI or HOWL? Werewolf Therapeutics has a consensus price target of $8.33, suggesting a potential upside of 491.02%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Werewolf Therapeutics is more favorable than Organigram Global.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram Global 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Werewolf Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, OGI or HOWL? Organigram Global has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Does the media refer more to OGI or HOWL? In the previous week, Organigram Global and Organigram Global both had 1 articles in the media. Organigram Global's average media sentiment score of 0.00 equaled Werewolf Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organigram Global 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in OGI or HOWL? 34.6% of Organigram Global shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 0.1% of Organigram Global shares are held by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is OGI or HOWL more profitable? Organigram Global has a net margin of 8.05% compared to Werewolf Therapeutics' net margin of 0.00%. Organigram Global's return on equity of -5.93% beat Werewolf Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Organigram Global8.05% -5.93% -4.39% Werewolf Therapeutics N/A -89.37%-54.87% Which has stronger earnings and valuation, OGI or HOWL? Organigram Global has higher revenue and earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Organigram Global, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganigram Global$117.47M1.65-$33.39M$0.1014.50Werewolf Therapeutics$1.88M33.65-$70.51M-$1.67-0.84 SummaryOrganigram Global beats Werewolf Therapeutics on 8 of the 14 factors compared between the two stocks. Get Werewolf Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOWL vs. The Competition Export to ExcelMetricWerewolf TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.82M$2.96B$5.55B$9.41BDividend YieldN/A2.47%3.75%4.03%P/E Ratio-0.8419.7528.0119.82Price / Sales33.65300.10432.6698.27Price / CashN/A42.5936.1658.27Price / Book0.857.678.125.65Net Income-$70.51M-$55.28M$3.25B$257.91M7 Day Performance18.49%4.85%1.68%3.38%1 Month Performance13.71%11.70%7.30%11.11%1 Year Performance-48.16%3.69%32.89%18.99% Werewolf Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOWLWerewolf Therapeutics3.5061 of 5 stars$1.41+0.7%$8.33+491.0%-49.1%$62.82M$1.88M-0.8440News CoverageGap UpOGIOrganigram Global0.8609 of 5 stars$1.39-2.8%N/A-10.5%$191.53M$117.47M13.90860NLTXNeoleukin TherapeuticsN/A$20.09+1.7%N/A-49.0%$188.81MN/A-6.4690PROKProKidney3.5415 of 5 stars$0.61-4.8%$3.50+477.1%+43.8%$186.51M$306K-1.013Analyst ForecastALMSAlumis2.6423 of 5 stars$3.31-2.6%$22.86+590.5%-73.4%$184.98MN/A0.00N/ANews CoverageGap DownELDNEledon Pharmaceuticals1.8391 of 5 stars$3.11+1.0%$9.00+189.4%+39.6%$184.44MN/A-1.4810CYBNCybin3.0583 of 5 stars$7.87-0.9%$86.00+992.8%N/A$181.20MN/A-1.8050News CoverageTILInstil Bio3.1477 of 5 stars$23.64-14.0%$119.00+403.4%+106.8%$180.37MN/A-1.97410Positive NewsHigh Trading VolumePBYIPuma Biotechnology4.1317 of 5 stars$3.54-1.1%$7.00+97.7%-8.1%$177.68M$230.50M4.60200Positive NewsVYGRVoyager Therapeutics4.0133 of 5 stars$3.04-5.0%$13.39+340.5%-61.6%$177.08M$80M-2.08100News CoverageTLSATiziana Life Sciences1.232 of 5 stars$1.53+1.3%N/A+82.4%$176.44MN/A0.008 Related Companies and Tools Related Companies Organigram Global Alternatives Neoleukin Therapeutics Alternatives ProKidney Alternatives Alumis Alternatives Eledon Pharmaceuticals Alternatives Cybin Alternatives Instil Bio Alternatives Puma Biotechnology Alternatives Voyager Therapeutics Alternatives Tiziana Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOWL) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
